Not a good buy right now for an impatient investor: the trend is bullish, but price is pressing near resistance with short-term momentum looking stretched.
Upside to the next technical levels looks limited in the very near term (around 9.67 then ~10), while downside risk to the pivot/support is meaningful (9.29 / 9.05).
Options positioning is bullish (call-heavy), but implied volatility is very high vs historical, suggesting the market is pricing a bigger move and making new exposure less attractive at this exact level.
Pattern-based forward view: Similar-pattern stats imply mild upside over a month (~+3.0%) but near-flat next day/week, which aligns with “good trend, mediocre immediate entry.”
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment (Open Interest): Put/Call OI ratio 0.26 (calls dominate: 1630 call OI vs 422 put OI) → bullish positioning.
Sentiment (Volume): Put/Call volume ratio 0.0 (only calls traded today; total volume is low at 10) → bullish but not strongly confirmed by activity.
Volatility: IV 30d 60.03 vs Historical Vol 30.21; IV percentile 80.48 → options market is pricing elevated movement/uncertainty and optionality is expensive.
Positioning/flow context: Today’s volume is below recent averages (10 vs 5d avg 15.6; 10d avg 24), so the bullish skew is more “positioning” than “fresh aggressive buying.”
Technical Summary
Sell
2
Buy
7
Positive Catalysts
Fundamentals improving: strong YoY growth in revenue, net income, and EPS in the latest reported quarter.
Technicals supportive: bullish moving-average stack plus positive MACD expansion.
Options positioning: call-heavy open interest suggests market participants lean bullish.
No negative headline flow in the past week (no new adverse catalyst surfaced in the provided feed).
Neutral/Negative Catalysts
70 while price is near resistance → higher odds of a near-term pullback or stall.
Takeaway: growth and earnings momentum are positive, but margin decline is a key watch item.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: JPMorgan maintains Neutral while lowering price targets (to $10 from $10.30 and to EUR 8.50 from EUR 9), reflecting a slightly more conservative outlook.
Wall Street pro view (pros): improving earnings profile; broader sector concerns around U.S. pricing pressure noted as having eased.
Wall Street con view (cons): neutral rating signals limited conviction; commentary suggests relative preference for names with clearer 2026 pipeline catalysts, implying GRFS may lack near-term “story” support.
Influential/political trading: No recent congress trading data available; insiders reported as Neutral (no notable recent activity).
Wall Street analysts forecast GRFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRFS is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast GRFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRFS is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Buy
Hold
Sell
0
Current: 9.190
Low
0
Averages
0
High
0
0
Current: 9.190
Low
0
Averages
0
High
0
JPMorgan
Neutral
downgrade
$10
AI Analysis
2025-12-08
Reason
JPMorgan
Price Target
$10
AI Analysis
2025-12-08
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Grifols to $10 from $10.30 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the European pharma group as part of its 2026 outlook. It expects sector performance to be driven by pipeline readouts, saying much of the concern around the impact of U.S. price pressure on sector earnings has dissipated in Q4. JPMorgan downgraded companies with a lack of pipeline readouts in 2026.
JPMorgan
Neutral
downgrade
2025-12-08
Reason
JPMorgan
Price Target
2025-12-08
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Grifols to EUR 8.50 from EUR 9 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GRFS
